Faster Way Of Recovery By Using The One Minute Cure For Cancer

Are you looking for more knowledge, information and reviews about The One Minute Cure, instructions on a faster way of recovery using the one minute cure for cancer? How to deal with cancer cells, swine flu, bacteria and kill disease cells? There are many approach and treatment available to stop diseases, but no one has been effective in fighting the cause of the problem. The One Minute Cure instruction claims to have the formula to help patients cure diseases.

* First Of All Is The One Minute Cure Been Scientifically Proven?

According to scientific researchers and professional health practitioners, this treatment has a faster way of recovery and is effective for treating cancer problems and every form of diseases. It is so safe as it is administering a natural oxygenating substance to deliver oxygen atoms from the bloodstream and distribute it into the cells of the body.

* Now, How Does The One Minute Cure formula Works?

This cure formula can be applied anytime with only one minute a day. And it has already proven that it provides a faster way of recovery and helped many people heal their diseases. Now According to scientific research oxygen therapy allows maximum transportation of blood to the body cells from the blood by increasing oxygen and hemoglobin disassociation.

* Why Do Cancer And Disease Cells Die When The One Minute Cure Is Applied to the Body?

Cancer cells and disease cells like viruses, pathogens, micro organisms cannot thrive in highly oxygenated environment because of their anaerobic nature, The One Minute Cure is able to kill cancer and diseases cells by saturating the body’s tissues and cells with oxygen. Now, the body has a faster way of recovery using the one minute cure for cancer.

* More information and instructions on How to deal with Diseases and Cancer problems.

A person who is sick and has a cancer problem has a very acidic condition. Normally all sick people are acidic and the result is extreme fatigue. We must also remember that cancer and disease cells thrive and multiply in acidic system. Now, in layman’s term oxygen therapy destroys acidity and establishes and alkaline system within with a ph of 7.2 and above. Now, there are also activities that destroys and acidic conditions like relaxation, yoga, exercising and massage therapy to help deal with cancer.

This approach proves and provides a faster way of recovery using the one minute cure for cancer.

Sclerotherapy for Varicose Veins

Varicose Veins (veins that have become enlarged and twisted) can happen to anyone. They occur in the legs and not only look ugly as they grow bigger, but also make movement uncomfortable. However, varicose veins can be treated through sclerotherapy – a medical procedure in use since the 1930s for removal of varicose veins and spider veins. Sclerotherapy basically requires injecting a special chemical known as sclerosant precisely into the damaged vein. Sclerotherapy is normally done in a doctor’s chamber and the entire treatment session takes anything between five minutes and an hour depending on the number of varicose veins are being treated.

The Treatment

During the treatment of varicose veins using sclerotherapy, cosmetic injection is administered directly into the enlarged or varicose veins aggravating the inside layer of the damaged blood vessels. The aethoxysklerol injection makes the varicose veins swell up and attach together. This leads to the clotting of blood inside the varicose veins. Eventually, the varicose veins are converted into a blemished tissue and become paler before fading away. During this process the affected leg is put on an elevated stand to draw off blood before administering and buy aethoxysklerol injection into the varicose veins. It is essential to apply pressure over the varicose veins after administering aethoxysklerol injections with a view to stop blood from returning when the patient stands up. The patient may be required to put on compression stocking or stretch bandages for a number of days after the vein removal treatment to sustain the pressure on the affected leg.

In fact, using aethoxysklerol injections for removal of varicose vein is quite painful and the sclerosant contained in the aethoxysklerol injections may cause burning or cramping sensations at the site of the injection. Normally, depending on the degree of varicose veins and the type of sclerosant used in the injections, a patient having varicose veins may require several shots of the aethoxysklerol injections. Several researches have established that removal of varicose veins as many as 50 to 80 per cent is possible with each session of sclerotherapy. Only less than 10 per cent of the people who have sclerotherapy do not respond to the aethoxysklerol injections at all. Normally, spider veins respond to the treatment in three to six weeks, and larger varicose veins respond in three to four months.

Side Effects

Using sclerotherapy for removal of varicose veins is associated with certain side effects. It has been commonly found that removal of vein by administering aethoxysklerol injections often change the color of the skin along the cured varicose veins. While the discoloration may cause a permanent scar in some people using aethoxysklerol injections, in others it may take six months to a year to fade away. Patients using sclerotherapy for removal of varicose veins may also experience pain, bruising, itching and blistering at the site where the aethoxysklerol injections have been administered. In the event aethoxysklerol injection is shot outside the varicose veins, it may result to ulcers or death of the tissues around the area. Sclerotherapy may also lead to blood clots or injure the deep vein system. One of the major risks of using sclerotherapy for removal of varicose veins is the failure of the treatment to put off the return of varicose veins at a later stage.

Precautions

People who have been administered aethoxysklerol injections for removal of varicose veins would likely be able to walk immediately after the treatment, but they need to take it easy for a couple of days. Although bed rest is not recommended after the vein removal treatment, patients should avoid all strenuous activities for a few days after sclerotherapy. Sclerotherapy should not be used in women with varicose veins who are pregnant or lactating. This is primarily owing to the fact that so far it has not been ascertained whether the chemical sclerosant used in aethoxysklerol injections leads to birth defects or gets into breast milk. Aethoxysklerol injections should not be administered to people having a history of allergy to sclerosant or comparable substances. In addition, aethoxysklerol injections may prove to be detrimental to the health of people having blood clots or inflammation in the deep leg veins. People taking aethoxysklerol injections for removal of varicose veins should also not take hot baths, hot compresses, whirlpools or saunas or come under direct exposure to sunlight for a few days after the treatment. Always remember, sclerotherapy done for cosmetic purpose is not covered under insurance.

Wrapping Up

There are several benefits of using sclerotherapy for treating varicose veins. While sclerotherapy is inexpensive compared to surgery, removal of varicose vein through this medical procedure does not require the patient to be admitted to hospital. At the same time, vein removal using sclerotherapy enables a person to return to work and normal activities much quickly. In addition, sclerotherapy also diminishes symptoms and improves the appearance of the skin in 85 per cent of people who have smaller varicose veins.

Cystic Fibrosis Axentis Pharma Initiates Clinical Trial For Lung Infections

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug. Initial results are expected in summer 2009. Axentis Pharma acquired all the necessary rights for this formulation from international partners just eight months ago. In addition to these advances, the company has also succeeded in appointing two renowned experts to its Scientific Advisory Board.

Axentis Pharma AG (Switzerland) announced today that all the necessary requirements for a clinical phase IIa trial have been fulfilled. The objective of this trial is to assess the safety and tolerability of an inhalable tobramycin, a well characterised and established drug for the treatment of pulmonary infection in cystic fibrosis patients. The product ARB-CF0223 also known as Fluidosome(R) tobramycin is a liposomal formulation of tobramycin, delivered directly to the site of infection via standard nebulizers. ARB-CF0223 has an improved safety profile and higher efficacy compared to current treatments for infections of the respiratory tract in patients with cystic fibrosis. It can be used in lower doses and also reduces the frequency and severity of side effects for pulmonary infections. The company expects to begin recruiting patients at its four international trial centres by the end of the year.

Dr. Hans Schreier, Chief Scientist of Axentis Pharma on the advances the company has made: "It was only very recently that we obtained all the necessary legal rights including transfer of sponsorship of the EMEA Orphan Designation to further develop our current lead product, Fluidosome(R) tobramycin. However, we are already in a position to initiate clinical trials to fully assess its safety and tolerability and gather information on appropriate doses. I am very pleased for patients suffering from cystic fibrosis, who will benefit directly from this promising once-a-day treatment: a significant improvement both in treatment and patient management. This is also great news for our investors, who have helped us to advance so far in a very short time."

Fluidosome(R) technology is based on the well characterised drug tobramycin. Utilising synthetic liposomes containing tobramycin, a standard nebulizer delivers the drug directly to the endobronchial sites of infection in cystic fibrosis patients. This results in prolonged, high local drug concentration, which in turn achieves higher efficacy and enables lower doses.

The phase II study will be carried out in 4 international centres. A total of 24 patients will receive treatment: Eight will receive a twice-daily 300 mg dose of the current tobramycin formulation over 28 days; another eight will be given a twice-daily 150 mg dose of Fluidosome(R) over two weeks and later a third group will receive one 300 mg dose of Fluidosome(R) per day for two weeks.

The company has also announced the appointment of two renowned experts to its Scientific Advisory Board. Prof. Adriano Aguzzi, Director of the Institute of Neuropathology at University Hospital Zurich, Switzerland and Prof. Gergely C. Lukacs, Canada Research Chair, Department of Physiology at McGill University Montreal, Canada will in future advise Axentis Pharma on scientific and medical issues related to the company's product pipeline.

Dr. Schreier on the latest additions to the team: "Axentis Pharma is very happy to have such outstanding experts on its Scientific Advisory Board. Just as our investors provide us with the trust and financial means that are essential to the ongoing development of our products, Prof. Aguzzi and Prof. Lukacs will contribute to the intellectual capital of Axentis Pharma."

About cystic fibrosis

Cystic fibrosis is the most common life-threatening hereditary disease amongst Caucasian populations. The disease is caused by a mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene found on chromosome 7. This mutation causes increased secretion deposits on mucous membranes. Lung complications represent the most serious manifestation of the disease ­ and the reason for the high mortality rate amongst patients. Such complications often involve infection of the bronchi by the bacteria Pseudomonas aeruginosa. Chronic inflammations then cause lung functions to become blocked. Besides the break-down of lung tissue, this also leads to bronchiectasis and lung failure.

About Axentis Pharma AG

Axentis Pharma AG is a Swiss biotechnology company. The company is using a patent-pending platform technology to develop therapies for diseases caused by incorrect protein folding in the endoplasmic reticulum. The most prominent example of such diseases is cystic fibrosis (mucoviscidosis).

About Fluidosome(R) technology

Axentis Pharma's Fluidosome(R) technology uses biocompatible lipids endogenous to the lung that are formulated into small liposomes. This nanocapsules platform opens broad applicability for unmet medical needs including other respiratory diseases. In the case of the Fluidosome tobramycin(R), the interaction between tobramycin and the microbial cell is triggered when the liposomes attach to the outer cell membrane. Tobramycin then leaches into the inner cell compartment, which leads to rapid cell death.